Icon
+91 94997 68112
Login Register

Toviaz - (4 mg, 8mg, Tablet, Extended Release)

FESOTERODINE FUMARATE Pfizer
4 mg, 8mg, Tablet, Extended Release
Less Than $1000 mn
More Than 5
More Than 5
More Than 5
Less Than 5
More Than 5
More Than 5
Used to treat overactive bladder with symptoms of urinary frequency, urgency, and incontinence
Yes
*****, ******, *****, ********, *****, ******, ***** *** ********* **** ** ** *** **** ***** **** ***** * **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****). ***** ******, ***** *** ****** **** ***** **** ** **** *** **** ******* *** **** ************ *********. *** *** ********* ****** ******, ********, ******, ******, ***** ******** * ********** **** ****** ***** *** ***** ** ********** *** *** *****. ***** *** ***** ***** ** ****** ** ****** ******* **** ******* '***, '*** *** '*** *** ***** *** ********* ** ******, ********, ******, ******, ***** . **** ***** ********* ****** ***** *** ****** ****** **** *, ****. ******* *****, ******, ******, *********, ***** *** ***** ******* * ********** ***** ** *** ******* ** ****** ***** ********* ***** ****** **** **** ****** **** *, ****. ******* *** ** ***** **** ********, ******, *******, *****, *******, ***, ******, ********* ******** ********* *********. ***** ** *** ****** ** **** ** ****** ** ***, ******* *** ******* ****** ***** ********* **** *** ********* ********. **** ***** ** *****'*, ********* *** ******* **** ***** * **** ** *** **** ************ ********. ********** *** ********* **** ** *****'*, ********* *** ******* ** ****.
Toviaz Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8
****** ****** *****(**** ** **) ****** *****(**** ** **) ******* ****** *****(**** ** **) ******* ******* ******* *******
***** ******* ******* ******* ******* ******* ******* ******* *******
***** ****** ******* ******* ******* ******* ******* ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ** *** **, **** ******* ********* ******** *** ****** **** ****
***** *** \ ** *** **, **** ******* ******** ******** ** *** **, ****
***** ****** *** \ ** *** **, **** ******* ******** ******** ** *** *, ****
  1. *** **, **** : ***** *** ****** ******** ****** ***** ***** **** ** **** *******'*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  2. *** **, **** : ****** ***** **** ******* ***** *** ****** ** ******** ***** ** ********.
  3. *** **, **** : *****, ********, *****, ******, ***** *** *********, ****** ******** ****** ***** ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  4. *** **, **** : ****** ***** * **** ******* *****, ********, *****, ******, *****,****** *** ********* ** ******** ***** ** ********.
  5. *** **, **** : ****** *** ****** ******** ***** ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  6. *** **, **** : ****** ***** * **** ******* ****** *** ****** ** ******** ***** ** ********.
  7. *** **, **** : ****** ***** * **** ******* ***** ** ******** ***** ** ******** ** ***** ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  8. *** *, **** : ********** *** ********* **** *** *** ********* ****** ******, ********, ******, ******, *****.
  9. *** **, **** : ***** ***** ** ****** ** ****** ** ****** *** ******* '*** *** '*** ** ***** *** ********* ** ******, ********, ******, ******.
  10. *** **, **** : ***** ***** ****** '*** ** ***** *** ********* ** ******, ********, ******, ******.
  11. *** **, **** : ****** ***** * **** ******* ** *****'* ** ** *****'* ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  12. *** *, **** : ********** *** ********* **** ** *****'*.
  13. *** **, **** : ****** ***** * **** ******* ********* ** ********* ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  14. *** *, **** : ********** *** ********* **** *********.
  15. *** *, **** : ****** ***** * **** ******* ******* ** ******* ***** **** ** **** ******* '*** (**** *, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), ‘*** (*** **, ****), *** ‘*** (*** **, ****).
  16. *** *, **** : ********* *** ********* **** *******.
  17. *** **, **** : ***** ***** ******* '***, '***, '***, '*** ** ***** *** ********* ** *****. ***** ******** *** ******** ** ******* *******.
  18. *** **, **** : ********** *** ********* **** *****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.